Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | One Johnson & Johnson Plaza NEW BRUNSWICK NJ 08933 |
Tel: | 1-800-9505089 |
Website: | https://www.jnj.com |
IR: | See website |
Key People | ||
Joaquin Boix Duato Chairman of the Board, Chief Executive Officer | Tim Schmid Executive Vice President, Worldwide Chairman of MedTech | Joseph J. Wolk Chief Financial Officer, Executive Vice President |
Peter M. Fasolo Chief Human Resource Officer, Executive Vice President | Kathryn E. Wengel Executive Vice President, Chief Technology Officer and Risk Officer | James Swanson Executive Vice President, Chief Information Officer |
Elizabeth Forminard Executive Vice President, General Counsel | Vanessa Broadhurst Executive Vice President - Global Corporate Affairs | William N. Hait Executive Vice President, Chief External Innovation and Medical Officer | John C. Reed Executive Vice President - Innovative Medicine, Research and Development |
Business Overview |
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, and vision fields. These products are distributed to wholesalers, hospitals, and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. |
Financial Overview |
For the fiscal year ended 31 December 2023, Johnson & Johnson revenues increased 6% to $85.16B. Net income before extraordinary items decreased 19% to $13.33B. Revenues reflect MedTech segment increase of 11% to $30.4B, Innovative Medicine segment increase of 4% to $54.76B, United States segment increase of 11% to $46.44B, International segment increase of 2% to $38.72B. |
Employees: | 131,900 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $387,054M as of Dec 31, 2023 |
Annual revenue (TTM): | $85,159M as of Dec 31, 2023 |
EBITDA (TTM): | $30,987M as of Dec 31, 2023 |
Net annual income (TTM): | $13,326M as of Dec 31, 2023 |
Free cash flow (TTM): | $6,478M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $6,405M as of Dec 31, 2023 |
Shares outstanding: | 2,409,783,054 as of Feb 27, 2024 |
Index Membership: | S&P 500, Dow Industry |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |